Funding will expand the range of Dualase(R) genome editors for new high morbidity and mortality genetic disease targets. TORONTO, March 18, 2026 /CNW/ - Specific Biologics Inc. ("Specific"), a ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The latest biotech industry insights, including a publication demonstrating dramatic lifespan extension in aging mouse models.

As climate pressure mounts, new platforms tackle delivery, regulation, trait stacking, and data bottlenecks limiting agricultural genome editing.

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Overview of the tobacco rattle virus-mediated genome editing system in tobacco plants. A 20-nucleotide target sequence is cloned before the sgRNA scaffold under the PEBV promoter in the pTRV2-PEBV ...

Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient’s cells. However, most genetic disorders are caused by dozens or even thousands of ...

Pakistan and China would undertake joint research in advanced agricultural technologies including genomics, genome editing and speed breeding to improve crop productivity, Director General ...

Specific Biologics Inc. ("Specific"), a biotechnology company developing industry-leading in vivo genome editing medicines to treat the untreatable, today announced that together with Western ...